Results 41 to 50 of about 22,412 (196)

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source

Case Report: Heparin-induced thrombocytopenia during COVID-19 outbreak: the importance of scoring system in differentiating with sepsis-induced coagulopathy [version 2; peer review: 2 approved]

F1000Research, 2021
Background: COVID-19 disease is accompanied by derangement of coagulation with a risk of fatal thromboembolic formation. COVID-19 patients are among those indicative for heparin treatment.
Louisa Fadjri Kusuma Wardhani, Ivana Purnama Dewi, Denny Suwanto, Ade Meidian Ambari, Meity Ardiana   +4 more
doaj   +1 more source

Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

Journal of Clinical Laboratory Analysis, EarlyView.
The influences of bivalirudin on fibrinogen assays differ considerably. Activated carbon can effectively remove bivalirudin from plasma, thereby eliminating its interference in fibrinogen detection. ABSTRACT Background Direct thrombin inhibitors may lead to falsely low fibrinogen results.
Jia Du, Haiyan Liu, Xiaohui Liu, Shuzheng Cao, Zhenlu Zhang, Litao Zhang   +5 more
wiley   +1 more source

Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice

Journal of Hospital Medicine, EarlyView.
Abstract Background The American Society of Hematology (ASH) recommends assessing venous thromboembolism (VTE) and major bleeding risk to optimize pharmacological VTE prophylaxis for medical inpatients. However, the clinical utility of model‐guided approaches remains unknown.
Benjamin G Mittman, Michael B. Rothberg
wiley   +1 more source

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism

Case Reports in Hematology, 2017
Heparin-induced thrombocytopenia (HIT) is a prothrombotic adverse drug reaction in which heparin forms complexes with platelet factor 4 forming neoantigens that are recognized by autoantibodies.
Samuel Adediran, Nicole Agostino
doaj   +1 more source

Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. Heparin-induced thrombocytopenia associated to hemodialysis is rare. In case when citrate dialysis and/or non-heparin anticoagulants are not available, only possible medication to use for anticoagulation during hemodialysis is ...
Kušić Jovana, Kulić Andrijana, Đurković Veselinka, Marković Rodoljub, Milačić Velja, Surić-Lambić Ljiljana, Peković Gordana   +6 more
doaj   +1 more source

Autoimmune heparin‐induced thrombocytopenia [PDF]

Journal of Thrombosis and Haemostasis, 2017
Autoimmune heparin-induced thrombocytopenia (aHIT) indicates the presence in patients of anti-platelet factor 4 (PF4)-polyanion antibodies that are able to activate platelets strongly even in the absence of heparin (heparin-independent platelet activation).
A, Greinacher, K, Selleng, T E, Warkentin   +2 more
openaire   +2 more sources

Medical haematology: Repositioning haematology at the centre of medicine

British Journal of Haematology, EarlyView.
The complementary domains of Medical Haematology and Haemato‐Oncology share a biological framework. The left panel depicts red cells, platelets, coagulation, thrombosis and innate immunity, while the right panel shows lymphoid and myeloid malignancies.
Cheng Hock Toh, Imelda Bates, Sue Pavord
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Heparin-induced thrombocytopenia

Blood Reviews, 1999
Heparin-induced thrombocytopenia with or without thrombosis has been recognized increasingly as a serious complication of heparin use. This article reviews type II heparin-induced thrombocytopenia, which is mediated by an antibody that in most cases has specificity for a complex between heparin and platelet factor 4, a secreted platelet alpha-granule ...
K L, Kaplan, C W, Francis
openaire   +2 more sources